SynBiotic SE (ETR:SBX)

Market Cap	8.61M -58.7%
Revenue (ttm)	14.86M +172.0%
Net Income	-9.72M
EPS	-1.66
Shares Out	6.82M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,695
Open	1.212
Previous Close	1.262
Day's Range	1.210 - 1.226
52-Week Range	1.000 - 3.845
Beta	0.68
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 17, 2026

About SynBiotic SE

SynBiotic SE engages in the research and development, production, and marketing of cannabinoid and terpene-based solutions to for pain, sleep deprivation, and anxiety. It also offers hemp, cannabinoids, dietary supplements, and cosmetic products; medical cannabis products; and cannabis products for recreational use under the Hempamed, Princess Stardust, The Hempany, and Hempamed Rx brand names. The company was formerly known as Ledgertech SE and changed its name to SynBiotic SE. SynBiotic SE was founded in 2017 and is based in Munich, Germany.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2017
• Employees: 55
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: SBX

Financial Performance

In 2024, SynBiotic SE's revenue was 14.89 million, an increase of 285.49% compared to the previous year's 3.86 million. Losses were -9.72 million, -8.60% less than in 2023.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 24, 2026

Data Sources Report a data error